NCT01470118

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 127 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.

Conditions

• Conjunctivitis, Allergic

Interventions

Type	Name	Description
DRUG	alcaftadine 0.25% ophthalmic solution	One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
DRUG	olopatadine 0.2% ophthalmic solution	One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
DRUG	dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%	One drop of placebo instilled in each eye at Day 0 and Day 14.

Timeline

• Start date: 2011-10-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2011-11-11
• Last updated: 2013-02-21
• Results posted: 2013-02-21

Locations

1 site across 1 country: United States